nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—UGT2B7—urinary bladder cancer	0.412	0.858	CbGaD
Naproxen—AKR1C3—Doxorubicin—urinary bladder cancer	0.0797	0.258	CbGbCtD
Naproxen—PTGS2—urinary bladder cancer	0.0679	0.141	CbGaD
Naproxen—UGT2B7—Epirubicin—urinary bladder cancer	0.0468	0.151	CbGbCtD
Naproxen—UGT1A1—Etoposide—urinary bladder cancer	0.0315	0.102	CbGbCtD
Naproxen—PTGS2—Cisplatin—urinary bladder cancer	0.0193	0.0624	CbGbCtD
Naproxen—PTGS2—Etoposide—urinary bladder cancer	0.019	0.0613	CbGbCtD
Naproxen—PTGS1—Etoposide—urinary bladder cancer	0.016	0.0517	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—urinary bladder cancer	0.0153	0.0494	CbGbCtD
Naproxen—ALB—Fluorouracil—urinary bladder cancer	0.0143	0.0463	CbGbCtD
Naproxen—CYP2C8—Fluorouracil—urinary bladder cancer	0.0111	0.0358	CbGbCtD
Naproxen—SLC22A6—Methotrexate—urinary bladder cancer	0.00928	0.03	CbGbCtD
Naproxen—CYP2C8—Etoposide—urinary bladder cancer	0.00924	0.0299	CbGbCtD
Naproxen—CYP1A2—Fluorouracil—urinary bladder cancer	0.00857	0.0277	CbGbCtD
Naproxen—ALB—Methotrexate—urinary bladder cancer	0.0079	0.0255	CbGbCtD
Naproxen—CYP2C9—Fluorouracil—urinary bladder cancer	0.00772	0.025	CbGbCtD
Naproxen—CYP1A2—Etoposide—urinary bladder cancer	0.00715	0.0231	CbGbCtD
Naproxen—CYP2C9—Cisplatin—urinary bladder cancer	0.00656	0.0212	CbGbCtD
Naproxen—UGT1A1—urine—urinary bladder cancer	0.00373	0.138	CbGeAlD
Naproxen—AKR1C3—Podofilox—Etoposide—urinary bladder cancer	0.00185	1	CbGdCrCtD
Naproxen—CYP1A2—urine—urinary bladder cancer	0.00165	0.0613	CbGeAlD
Naproxen—UGT2B7—prostate gland—urinary bladder cancer	0.00157	0.0584	CbGeAlD
Naproxen—CYP2C9—urine—urinary bladder cancer	0.00157	0.0581	CbGeAlD
Naproxen—AKR1C3—prostate gland—urinary bladder cancer	0.00145	0.0539	CbGeAlD
Naproxen—UGT1A1—prostate gland—urinary bladder cancer	0.00134	0.0497	CbGeAlD
Naproxen—AKR1C3—seminal vesicle—urinary bladder cancer	0.00123	0.0456	CbGeAlD
Naproxen—UGT2B7—renal system—urinary bladder cancer	0.00107	0.0398	CbGeAlD
Naproxen—AKR1C3—smooth muscle tissue—urinary bladder cancer	0.00103	0.0381	CbGeAlD
Naproxen—AKR1C3—urethra—urinary bladder cancer	0.000971	0.0361	CbGeAlD
Naproxen—UGT1A1—renal system—urinary bladder cancer	0.000912	0.0339	CbGeAlD
Naproxen—UGT2B7—female reproductive system—urinary bladder cancer	0.000859	0.0319	CbGeAlD
Naproxen—Suprofen—UGT2B7—urinary bladder cancer	0.000742	0.166	CrCbGaD
Naproxen—AKR1C3—vagina—urinary bladder cancer	0.000716	0.0266	CbGeAlD
Naproxen—SLCO1A2—renal system—urinary bladder cancer	0.000617	0.0229	CbGeAlD
Naproxen—Nabumetone—MPO—urinary bladder cancer	0.000553	0.124	CrCbGaD
Naproxen—PTGS1—prostate gland—urinary bladder cancer	0.000513	0.0191	CbGeAlD
Naproxen—PTGS2—prostate gland—urinary bladder cancer	0.000491	0.0182	CbGeAlD
Naproxen—Indomethacin—UGT2B7—urinary bladder cancer	0.000472	0.105	CrCbGaD
Naproxen—AKR1C3—lymph node—urinary bladder cancer	0.000463	0.0172	CbGeAlD
Naproxen—PTGS1—seminal vesicle—urinary bladder cancer	0.000434	0.0161	CbGeAlD
Naproxen—CYP2C8—renal system—urinary bladder cancer	0.000431	0.016	CbGeAlD
Naproxen—Flurbiprofen—UGT2B7—urinary bladder cancer	0.000417	0.0932	CrCbGaD
Naproxen—PTGS2—seminal vesicle—urinary bladder cancer	0.000415	0.0154	CbGeAlD
Naproxen—CYP1A2—renal system—urinary bladder cancer	0.000404	0.015	CbGeAlD
Naproxen—PTGS1—epithelium—urinary bladder cancer	0.000377	0.014	CbGeAlD
Naproxen—Ibuprofen—UGT2B7—urinary bladder cancer	0.000371	0.083	CrCbGaD
Naproxen—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000363	0.0135	CbGeAlD
Naproxen—PTGS2—epithelium—urinary bladder cancer	0.000361	0.0134	CbGeAlD
Naproxen—PTGS1—renal system—urinary bladder cancer	0.00035	0.013	CbGeAlD
Naproxen—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000347	0.0129	CbGeAlD
Naproxen—CYP2C8—female reproductive system—urinary bladder cancer	0.000346	0.0128	CbGeAlD
Naproxen—PTGS2—renal system—urinary bladder cancer	0.000334	0.0124	CbGeAlD
Naproxen—PTGS2—urethra—urinary bladder cancer	0.000328	0.0122	CbGeAlD
Naproxen—CYP2C8—vagina—urinary bladder cancer	0.000312	0.0116	CbGeAlD
Naproxen—CYP2C9—female reproductive system—urinary bladder cancer	0.000307	0.0114	CbGeAlD
Naproxen—ALB—lymph node—urinary bladder cancer	0.000288	0.0107	CbGeAlD
Naproxen—PTGS1—female reproductive system—urinary bladder cancer	0.00028	0.0104	CbGeAlD
Naproxen—PTGS2—female reproductive system—urinary bladder cancer	0.000268	0.00994	CbGeAlD
Naproxen—Indomethacin—CXCL8—urinary bladder cancer	0.000266	0.0595	CrCbGaD
Naproxen—PTGS1—vagina—urinary bladder cancer	0.000253	0.00941	CbGeAlD
Naproxen—PTGS2—vagina—urinary bladder cancer	0.000242	0.00899	CbGeAlD
Naproxen—Ketoprofen—CXCL8—urinary bladder cancer	0.000213	0.0476	CrCbGaD
Naproxen—Ibuprofen—CXCL8—urinary bladder cancer	0.00021	0.0469	CrCbGaD
Naproxen—Nabumetone—PTGS2—urinary bladder cancer	0.000207	0.0463	CrCbGaD
Naproxen—Carprofen—PTGS2—urinary bladder cancer	0.000198	0.0442	CrCbGaD
Naproxen—Indomethacin—PPARG—urinary bladder cancer	0.000184	0.0411	CrCbGaD
Naproxen—PTGS1—lymph node—urinary bladder cancer	0.000164	0.00609	CbGeAlD
Naproxen—PTGS2—lymph node—urinary bladder cancer	0.000157	0.00582	CbGeAlD
Naproxen—Ibuprofen—PPARG—urinary bladder cancer	0.000145	0.0324	CrCbGaD
Naproxen—Suprofen—PTGS2—urinary bladder cancer	0.000122	0.0273	CrCbGaD
Naproxen—Fenoprofen—PTGS2—urinary bladder cancer	0.000105	0.0235	CrCbGaD
Naproxen—Indomethacin—PTGS2—urinary bladder cancer	7.77e-05	0.0174	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—urinary bladder cancer	6.87e-05	0.0154	CrCbGaD
Naproxen—Ketoprofen—PTGS2—urinary bladder cancer	6.22e-05	0.0139	CrCbGaD
Naproxen—Ibuprofen—PTGS2—urinary bladder cancer	6.12e-05	0.0137	CrCbGaD
Naproxen—Sweating—Doxorubicin—urinary bladder cancer	4.38e-05	0.000363	CcSEcCtD
Naproxen—Urinary tract disorder—Epirubicin—urinary bladder cancer	4.38e-05	0.000363	CcSEcCtD
Naproxen—Oedema peripheral—Epirubicin—urinary bladder cancer	4.37e-05	0.000362	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—urinary bladder cancer	4.36e-05	0.000361	CcSEcCtD
Naproxen—Connective tissue disorder—Epirubicin—urinary bladder cancer	4.36e-05	0.000361	CcSEcCtD
Naproxen—Urethral disorder—Epirubicin—urinary bladder cancer	4.35e-05	0.00036	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	4.32e-05	0.000358	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—urinary bladder cancer	4.31e-05	0.000357	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—urinary bladder cancer	4.3e-05	0.000356	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—urinary bladder cancer	4.29e-05	0.000356	CcSEcCtD
Naproxen—Immune system disorder—Methotrexate—urinary bladder cancer	4.28e-05	0.000355	CcSEcCtD
Naproxen—Dizziness—Fluorouracil—urinary bladder cancer	4.28e-05	0.000355	CcSEcCtD
Naproxen—Visual impairment—Epirubicin—urinary bladder cancer	4.27e-05	0.000354	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—urinary bladder cancer	4.27e-05	0.000354	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—urinary bladder cancer	4.27e-05	0.000354	CcSEcCtD
Naproxen—Chills—Methotrexate—urinary bladder cancer	4.25e-05	0.000353	CcSEcCtD
Naproxen—Diarrhoea—Cisplatin—urinary bladder cancer	4.2e-05	0.000348	CcSEcCtD
Naproxen—Erythema multiforme—Epirubicin—urinary bladder cancer	4.19e-05	0.000348	CcSEcCtD
Naproxen—Alopecia—Methotrexate—urinary bladder cancer	4.19e-05	0.000347	CcSEcCtD
Naproxen—Vomiting—Gemcitabine—urinary bladder cancer	4.18e-05	0.000347	CcSEcCtD
Naproxen—Mental disorder—Methotrexate—urinary bladder cancer	4.15e-05	0.000344	CcSEcCtD
Naproxen—Rash—Gemcitabine—urinary bladder cancer	4.15e-05	0.000344	CcSEcCtD
Naproxen—Dermatitis—Gemcitabine—urinary bladder cancer	4.15e-05	0.000344	CcSEcCtD
Naproxen—Eye disorder—Epirubicin—urinary bladder cancer	4.14e-05	0.000344	CcSEcCtD
Naproxen—Hypersensitivity—Etoposide—urinary bladder cancer	4.14e-05	0.000343	CcSEcCtD
Naproxen—Tinnitus—Epirubicin—urinary bladder cancer	4.13e-05	0.000343	CcSEcCtD
Naproxen—Erythema—Methotrexate—urinary bladder cancer	4.13e-05	0.000342	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—urinary bladder cancer	4.13e-05	0.000342	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—urinary bladder cancer	4.12e-05	0.000342	CcSEcCtD
Naproxen—Headache—Gemcitabine—urinary bladder cancer	4.12e-05	0.000342	CcSEcCtD
Naproxen—Cardiac disorder—Epirubicin—urinary bladder cancer	4.12e-05	0.000341	CcSEcCtD
Naproxen—Vomiting—Fluorouracil—urinary bladder cancer	4.11e-05	0.000341	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—urinary bladder cancer	4.11e-05	0.000341	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—urinary bladder cancer	4.1e-05	0.00034	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—urinary bladder cancer	4.1e-05	0.00034	CcSEcCtD
Naproxen—Rash—Fluorouracil—urinary bladder cancer	4.08e-05	0.000338	CcSEcCtD
Naproxen—Dermatitis—Fluorouracil—urinary bladder cancer	4.08e-05	0.000338	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—urinary bladder cancer	4.07e-05	0.000338	CcSEcCtD
Naproxen—Headache—Fluorouracil—urinary bladder cancer	4.05e-05	0.000336	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.05e-05	0.000336	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—urinary bladder cancer	4.04e-05	0.000335	CcSEcCtD
Naproxen—Asthenia—Etoposide—urinary bladder cancer	4.03e-05	0.000334	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.03e-05	0.000334	CcSEcCtD
Naproxen—Angiopathy—Epirubicin—urinary bladder cancer	4.02e-05	0.000334	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—urinary bladder cancer	4.02e-05	0.000333	CcSEcCtD
Naproxen—Immune system disorder—Epirubicin—urinary bladder cancer	4.01e-05	0.000332	CcSEcCtD
Naproxen—Mediastinal disorder—Epirubicin—urinary bladder cancer	4e-05	0.000331	CcSEcCtD
Naproxen—Chills—Epirubicin—urinary bladder cancer	3.98e-05	0.00033	CcSEcCtD
Naproxen—Pruritus—Etoposide—urinary bladder cancer	3.98e-05	0.00033	CcSEcCtD
Naproxen—Arrhythmia—Epirubicin—urinary bladder cancer	3.96e-05	0.000328	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—urinary bladder cancer	3.95e-05	0.000328	CcSEcCtD
Naproxen—Alopecia—Epirubicin—urinary bladder cancer	3.92e-05	0.000325	CcSEcCtD
Naproxen—Nausea—Gemcitabine—urinary bladder cancer	3.91e-05	0.000324	CcSEcCtD
Naproxen—Vomiting—Cisplatin—urinary bladder cancer	3.9e-05	0.000323	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—urinary bladder cancer	3.89e-05	0.000322	CcSEcCtD
Naproxen—Mental disorder—Epirubicin—urinary bladder cancer	3.89e-05	0.000322	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—urinary bladder cancer	3.88e-05	0.000322	CcSEcCtD
Naproxen—Rash—Cisplatin—urinary bladder cancer	3.87e-05	0.000321	CcSEcCtD
Naproxen—Dermatitis—Cisplatin—urinary bladder cancer	3.86e-05	0.00032	CcSEcCtD
Naproxen—Malnutrition—Epirubicin—urinary bladder cancer	3.86e-05	0.00032	CcSEcCtD
Naproxen—Erythema—Epirubicin—urinary bladder cancer	3.86e-05	0.00032	CcSEcCtD
Naproxen—Diarrhoea—Etoposide—urinary bladder cancer	3.85e-05	0.000319	CcSEcCtD
Naproxen—Nausea—Fluorouracil—urinary bladder cancer	3.84e-05	0.000319	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—urinary bladder cancer	3.83e-05	0.000318	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—urinary bladder cancer	3.83e-05	0.000317	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—urinary bladder cancer	3.83e-05	0.000317	CcSEcCtD
Naproxen—Anaemia—Methotrexate—urinary bladder cancer	3.81e-05	0.000316	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.81e-05	0.000316	CcSEcCtD
Naproxen—Flatulence—Epirubicin—urinary bladder cancer	3.8e-05	0.000315	CcSEcCtD
Naproxen—Tension—Epirubicin—urinary bladder cancer	3.79e-05	0.000314	CcSEcCtD
Naproxen—Nervousness—Epirubicin—urinary bladder cancer	3.75e-05	0.000311	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—urinary bladder cancer	3.72e-05	0.000309	CcSEcCtD
Naproxen—Malaise—Methotrexate—urinary bladder cancer	3.72e-05	0.000308	CcSEcCtD
Naproxen—Dizziness—Etoposide—urinary bladder cancer	3.72e-05	0.000308	CcSEcCtD
Naproxen—Muscle spasms—Epirubicin—urinary bladder cancer	3.71e-05	0.000308	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—urinary bladder cancer	3.71e-05	0.000307	CcSEcCtD
Naproxen—Vertigo—Methotrexate—urinary bladder cancer	3.71e-05	0.000307	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—urinary bladder cancer	3.7e-05	0.000307	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—urinary bladder cancer	3.69e-05	0.000306	CcSEcCtD
Naproxen—Chills—Doxorubicin—urinary bladder cancer	3.68e-05	0.000305	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—urinary bladder cancer	3.67e-05	0.000304	CcSEcCtD
Naproxen—Nausea—Cisplatin—urinary bladder cancer	3.64e-05	0.000302	CcSEcCtD
Naproxen—Vision blurred—Epirubicin—urinary bladder cancer	3.64e-05	0.000302	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—urinary bladder cancer	3.63e-05	0.000301	CcSEcCtD
Naproxen—Cough—Methotrexate—urinary bladder cancer	3.6e-05	0.000298	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—urinary bladder cancer	3.59e-05	0.000298	CcSEcCtD
Naproxen—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.58e-05	0.000297	CcSEcCtD
Naproxen—Convulsion—Methotrexate—urinary bladder cancer	3.57e-05	0.000296	CcSEcCtD
Naproxen—Vomiting—Etoposide—urinary bladder cancer	3.57e-05	0.000296	CcSEcCtD
Naproxen—Erythema—Doxorubicin—urinary bladder cancer	3.57e-05	0.000296	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—urinary bladder cancer	3.57e-05	0.000296	CcSEcCtD
Naproxen—Anaemia—Epirubicin—urinary bladder cancer	3.57e-05	0.000296	CcSEcCtD
Naproxen—Rash—Etoposide—urinary bladder cancer	3.54e-05	0.000294	CcSEcCtD
Naproxen—Dermatitis—Etoposide—urinary bladder cancer	3.54e-05	0.000294	CcSEcCtD
Naproxen—Headache—Etoposide—urinary bladder cancer	3.52e-05	0.000292	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—urinary bladder cancer	3.52e-05	0.000292	CcSEcCtD
Naproxen—Chest pain—Methotrexate—urinary bladder cancer	3.51e-05	0.000291	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—urinary bladder cancer	3.51e-05	0.000291	CcSEcCtD
Naproxen—Myalgia—Methotrexate—urinary bladder cancer	3.51e-05	0.000291	CcSEcCtD
Naproxen—Tension—Doxorubicin—urinary bladder cancer	3.51e-05	0.000291	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.49e-05	0.000289	CcSEcCtD
Naproxen—Malaise—Epirubicin—urinary bladder cancer	3.48e-05	0.000289	CcSEcCtD
Naproxen—Discomfort—Methotrexate—urinary bladder cancer	3.47e-05	0.000288	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—urinary bladder cancer	3.47e-05	0.000288	CcSEcCtD
Naproxen—Vertigo—Epirubicin—urinary bladder cancer	3.47e-05	0.000288	CcSEcCtD
Naproxen—Syncope—Epirubicin—urinary bladder cancer	3.46e-05	0.000287	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—urinary bladder cancer	3.46e-05	0.000286	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—urinary bladder cancer	3.43e-05	0.000285	CcSEcCtD
Naproxen—Palpitations—Epirubicin—urinary bladder cancer	3.41e-05	0.000283	CcSEcCtD
Naproxen—Confusional state—Methotrexate—urinary bladder cancer	3.39e-05	0.000281	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—urinary bladder cancer	3.39e-05	0.000281	CcSEcCtD
Naproxen—Cough—Epirubicin—urinary bladder cancer	3.37e-05	0.000279	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.37e-05	0.000279	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—urinary bladder cancer	3.37e-05	0.000279	CcSEcCtD
Naproxen—Convulsion—Epirubicin—urinary bladder cancer	3.34e-05	0.000277	CcSEcCtD
Naproxen—Infection—Methotrexate—urinary bladder cancer	3.34e-05	0.000277	CcSEcCtD
Naproxen—Nausea—Etoposide—urinary bladder cancer	3.34e-05	0.000277	CcSEcCtD
Naproxen—Hypertension—Epirubicin—urinary bladder cancer	3.33e-05	0.000276	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.31e-05	0.000275	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—urinary bladder cancer	3.3e-05	0.000274	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—urinary bladder cancer	3.3e-05	0.000274	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.3e-05	0.000273	CcSEcCtD
Naproxen—Chest pain—Epirubicin—urinary bladder cancer	3.29e-05	0.000272	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—urinary bladder cancer	3.29e-05	0.000272	CcSEcCtD
Naproxen—Myalgia—Epirubicin—urinary bladder cancer	3.29e-05	0.000272	CcSEcCtD
Naproxen—Anxiety—Epirubicin—urinary bladder cancer	3.28e-05	0.000272	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—urinary bladder cancer	3.27e-05	0.000271	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.26e-05	0.000271	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.25e-05	0.00027	CcSEcCtD
Naproxen—Discomfort—Epirubicin—urinary bladder cancer	3.25e-05	0.000269	CcSEcCtD
Naproxen—Malaise—Doxorubicin—urinary bladder cancer	3.22e-05	0.000267	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—urinary bladder cancer	3.21e-05	0.000266	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—urinary bladder cancer	3.21e-05	0.000266	CcSEcCtD
Naproxen—Anorexia—Methotrexate—urinary bladder cancer	3.21e-05	0.000266	CcSEcCtD
Naproxen—Syncope—Doxorubicin—urinary bladder cancer	3.2e-05	0.000266	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—urinary bladder cancer	3.2e-05	0.000265	CcSEcCtD
Naproxen—Confusional state—Epirubicin—urinary bladder cancer	3.18e-05	0.000263	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—urinary bladder cancer	3.16e-05	0.000262	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.15e-05	0.000261	CcSEcCtD
Naproxen—Oedema—Epirubicin—urinary bladder cancer	3.15e-05	0.000261	CcSEcCtD
Naproxen—Hypotension—Methotrexate—urinary bladder cancer	3.15e-05	0.000261	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.14e-05	0.00026	CcSEcCtD
Naproxen—Infection—Epirubicin—urinary bladder cancer	3.13e-05	0.000259	CcSEcCtD
Naproxen—Cough—Doxorubicin—urinary bladder cancer	3.12e-05	0.000258	CcSEcCtD
Naproxen—Shock—Epirubicin—urinary bladder cancer	3.1e-05	0.000257	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—urinary bladder cancer	3.09e-05	0.000257	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—urinary bladder cancer	3.09e-05	0.000256	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.08e-05	0.000256	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—urinary bladder cancer	3.08e-05	0.000256	CcSEcCtD
Naproxen—Tachycardia—Epirubicin—urinary bladder cancer	3.07e-05	0.000255	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.07e-05	0.000254	CcSEcCtD
Naproxen—Skin disorder—Epirubicin—urinary bladder cancer	3.06e-05	0.000254	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.05e-05	0.000253	CcSEcCtD
Naproxen—Insomnia—Methotrexate—urinary bladder cancer	3.04e-05	0.000252	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—urinary bladder cancer	3.04e-05	0.000252	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—urinary bladder cancer	3.04e-05	0.000252	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—urinary bladder cancer	3.04e-05	0.000252	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—urinary bladder cancer	3.03e-05	0.000251	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—urinary bladder cancer	3.02e-05	0.000251	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.02e-05	0.00025	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—urinary bladder cancer	3e-05	0.000249	CcSEcCtD
Naproxen—Anorexia—Epirubicin—urinary bladder cancer	3e-05	0.000249	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—urinary bladder cancer	3e-05	0.000249	CcSEcCtD
Naproxen—Somnolence—Methotrexate—urinary bladder cancer	2.99e-05	0.000248	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—urinary bladder cancer	2.97e-05	0.000247	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—urinary bladder cancer	2.96e-05	0.000246	CcSEcCtD
Naproxen—Hypotension—Epirubicin—urinary bladder cancer	2.94e-05	0.000244	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—urinary bladder cancer	2.94e-05	0.000244	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—urinary bladder cancer	2.93e-05	0.000243	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—urinary bladder cancer	2.92e-05	0.000242	CcSEcCtD
Naproxen—Oedema—Doxorubicin—urinary bladder cancer	2.92e-05	0.000242	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.91e-05	0.000241	CcSEcCtD
Naproxen—Fatigue—Methotrexate—urinary bladder cancer	2.9e-05	0.000241	CcSEcCtD
Naproxen—Infection—Doxorubicin—urinary bladder cancer	2.9e-05	0.00024	CcSEcCtD
Naproxen—Pain—Methotrexate—urinary bladder cancer	2.88e-05	0.000239	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.87e-05	0.000238	CcSEcCtD
Naproxen—Shock—Doxorubicin—urinary bladder cancer	2.87e-05	0.000238	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.86e-05	0.000237	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.85e-05	0.000237	CcSEcCtD
Naproxen—Insomnia—Epirubicin—urinary bladder cancer	2.85e-05	0.000236	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—urinary bladder cancer	2.85e-05	0.000236	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—urinary bladder cancer	2.83e-05	0.000235	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—urinary bladder cancer	2.83e-05	0.000235	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.82e-05	0.000234	CcSEcCtD
Naproxen—Dyspnoea—Epirubicin—urinary bladder cancer	2.81e-05	0.000233	CcSEcCtD
Naproxen—Somnolence—Epirubicin—urinary bladder cancer	2.8e-05	0.000232	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—urinary bladder cancer	2.78e-05	0.00023	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—urinary bladder cancer	2.77e-05	0.00023	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—urinary bladder cancer	2.77e-05	0.00023	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.75e-05	0.000228	CcSEcCtD
Naproxen—Decreased appetite—Epirubicin—urinary bladder cancer	2.74e-05	0.000227	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—urinary bladder cancer	2.72e-05	0.000226	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.72e-05	0.000226	CcSEcCtD
Naproxen—Fatigue—Epirubicin—urinary bladder cancer	2.72e-05	0.000225	CcSEcCtD
Naproxen—Constipation—Epirubicin—urinary bladder cancer	2.69e-05	0.000223	CcSEcCtD
Naproxen—Pain—Epirubicin—urinary bladder cancer	2.69e-05	0.000223	CcSEcCtD
Naproxen—Urticaria—Methotrexate—urinary bladder cancer	2.67e-05	0.000222	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—urinary bladder cancer	2.66e-05	0.000221	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—urinary bladder cancer	2.66e-05	0.000221	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.66e-05	0.00022	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—urinary bladder cancer	2.64e-05	0.000219	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—urinary bladder cancer	2.62e-05	0.000217	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—urinary bladder cancer	2.6e-05	0.000215	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—urinary bladder cancer	2.6e-05	0.000215	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—urinary bladder cancer	2.59e-05	0.000215	CcSEcCtD
Naproxen—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.58e-05	0.000214	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—urinary bladder cancer	2.57e-05	0.000213	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—urinary bladder cancer	2.53e-05	0.00021	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.52e-05	0.000209	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—urinary bladder cancer	2.51e-05	0.000208	CcSEcCtD
Naproxen—Urticaria—Epirubicin—urinary bladder cancer	2.5e-05	0.000208	CcSEcCtD
Naproxen—Pain—Doxorubicin—urinary bladder cancer	2.49e-05	0.000207	CcSEcCtD
Naproxen—Constipation—Doxorubicin—urinary bladder cancer	2.49e-05	0.000207	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—urinary bladder cancer	2.49e-05	0.000206	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—urinary bladder cancer	2.49e-05	0.000206	CcSEcCtD
Naproxen—Hypersensitivity—Methotrexate—urinary bladder cancer	2.48e-05	0.000206	CcSEcCtD
Naproxen—Asthenia—Methotrexate—urinary bladder cancer	2.42e-05	0.0002	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.4e-05	0.000199	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.38e-05	0.000198	CcSEcCtD
Naproxen—Pruritus—Methotrexate—urinary bladder cancer	2.38e-05	0.000197	CcSEcCtD
Naproxen—Hypersensitivity—Epirubicin—urinary bladder cancer	2.32e-05	0.000192	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—urinary bladder cancer	2.32e-05	0.000192	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—urinary bladder cancer	2.3e-05	0.000191	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—urinary bladder cancer	2.3e-05	0.000191	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—urinary bladder cancer	2.3e-05	0.000191	CcSEcCtD
Naproxen—Asthenia—Epirubicin—urinary bladder cancer	2.26e-05	0.000187	CcSEcCtD
Naproxen—Pruritus—Epirubicin—urinary bladder cancer	2.23e-05	0.000185	CcSEcCtD
Naproxen—Dizziness—Methotrexate—urinary bladder cancer	2.23e-05	0.000185	CcSEcCtD
Naproxen—Diarrhoea—Epirubicin—urinary bladder cancer	2.16e-05	0.000179	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.15e-05	0.000178	CcSEcCtD
Naproxen—Vomiting—Methotrexate—urinary bladder cancer	2.14e-05	0.000177	CcSEcCtD
Naproxen—Rash—Methotrexate—urinary bladder cancer	2.12e-05	0.000176	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—urinary bladder cancer	2.12e-05	0.000176	CcSEcCtD
Naproxen—Headache—Methotrexate—urinary bladder cancer	2.11e-05	0.000175	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—urinary bladder cancer	2.09e-05	0.000173	CcSEcCtD
Naproxen—Dizziness—Epirubicin—urinary bladder cancer	2.08e-05	0.000173	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—urinary bladder cancer	2.06e-05	0.000171	CcSEcCtD
Naproxen—Vomiting—Epirubicin—urinary bladder cancer	2e-05	0.000166	CcSEcCtD
Naproxen—Nausea—Methotrexate—urinary bladder cancer	2e-05	0.000166	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—urinary bladder cancer	1.99e-05	0.000165	CcSEcCtD
Naproxen—Rash—Epirubicin—urinary bladder cancer	1.99e-05	0.000165	CcSEcCtD
Naproxen—Dermatitis—Epirubicin—urinary bladder cancer	1.98e-05	0.000165	CcSEcCtD
Naproxen—Headache—Epirubicin—urinary bladder cancer	1.97e-05	0.000164	CcSEcCtD
Naproxen—Dizziness—Doxorubicin—urinary bladder cancer	1.93e-05	0.00016	CcSEcCtD
Naproxen—Nausea—Epirubicin—urinary bladder cancer	1.87e-05	0.000155	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—urinary bladder cancer	1.85e-05	0.000154	CcSEcCtD
Naproxen—Rash—Doxorubicin—urinary bladder cancer	1.84e-05	0.000152	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—urinary bladder cancer	1.84e-05	0.000152	CcSEcCtD
Naproxen—Headache—Doxorubicin—urinary bladder cancer	1.83e-05	0.000151	CcSEcCtD
Naproxen—Nausea—Doxorubicin—urinary bladder cancer	1.73e-05	0.000144	CcSEcCtD
Naproxen—AKR1C3—Metabolism—CREBBP—urinary bladder cancer	1.27e-05	0.000226	CbGpPWpGaD
Naproxen—AKR1C3—Disease—ERBB2—urinary bladder cancer	1.27e-05	0.000226	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTT1—urinary bladder cancer	1.26e-05	0.000224	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—FGFR3—urinary bladder cancer	1.25e-05	0.000222	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—urinary bladder cancer	1.25e-05	0.000221	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.25e-05	0.000221	CbGpPWpGaD
Naproxen—PTGS2—Disease—ENO2—urinary bladder cancer	1.24e-05	0.000219	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—TYMS—urinary bladder cancer	1.23e-05	0.000218	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	1.22e-05	0.000217	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.22e-05	0.000216	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTM1—urinary bladder cancer	1.22e-05	0.000216	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—NCOR1—urinary bladder cancer	1.22e-05	0.000216	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ESR1—urinary bladder cancer	1.22e-05	0.000216	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.19e-05	0.00021	CbGpPWpGaD
Naproxen—PTGS2—Disease—RBX1—urinary bladder cancer	1.17e-05	0.000208	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.17e-05	0.000207	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.17e-05	0.000207	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMP—urinary bladder cancer	1.16e-05	0.000207	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GPX1—urinary bladder cancer	1.16e-05	0.000206	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.16e-05	0.000206	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMP—urinary bladder cancer	1.16e-05	0.000205	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.15e-05	0.000205	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTP1—urinary bladder cancer	1.15e-05	0.000204	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ERCC2—urinary bladder cancer	1.14e-05	0.000203	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.13e-05	0.0002	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.12e-05	0.000198	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.12e-05	0.000198	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.11e-05	0.000198	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.11e-05	0.000197	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	1.1e-05	0.000195	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CDKN1A—urinary bladder cancer	1.09e-05	0.000193	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTEN—urinary bladder cancer	1.09e-05	0.000193	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	0.000191	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—MTHFR—urinary bladder cancer	1.07e-05	0.000191	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—TYMS—urinary bladder cancer	1.07e-05	0.00019	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CREBBP—urinary bladder cancer	1.07e-05	0.000189	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PLAU—urinary bladder cancer	1.06e-05	0.000189	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTM1—urinary bladder cancer	1.06e-05	0.000188	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—NCOR1—urinary bladder cancer	1.06e-05	0.000188	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.05e-05	0.000187	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IGF1—urinary bladder cancer	1.05e-05	0.000187	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.05e-05	0.000186	CbGpPWpGaD
Naproxen—PTGS2—Disease—JAG1—urinary bladder cancer	1.05e-05	0.000186	CbGpPWpGaD
Naproxen—ALB—Metabolism—NAT2—urinary bladder cancer	1.05e-05	0.000186	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—urinary bladder cancer	1.04e-05	0.000185	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	1.04e-05	0.000184	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EP300—urinary bladder cancer	1.04e-05	0.000184	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.03e-05	0.000184	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.03e-05	0.000184	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.03e-05	0.000182	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.02e-05	0.000181	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GPX1—urinary bladder cancer	1.01e-05	0.00018	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	1.01e-05	0.00018	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SRC—urinary bladder cancer	1.01e-05	0.000179	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1e-05	0.000178	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—TYMS—urinary bladder cancer	1e-05	0.000177	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ERCC2—urinary bladder cancer	9.95e-06	0.000177	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.88e-06	0.000175	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	9.88e-06	0.000175	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	9.88e-06	0.000175	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RHOA—urinary bladder cancer	9.64e-06	0.000171	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	9.51e-06	0.000169	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMP—urinary bladder cancer	9.48e-06	0.000168	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GPX1—urinary bladder cancer	9.46e-06	0.000168	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	9.36e-06	0.000166	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	9.29e-06	0.000165	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	9.1e-06	0.000161	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTEN—urinary bladder cancer	9.1e-06	0.000161	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—RRM2—urinary bladder cancer	9.09e-06	0.000161	CbGpPWpGaD
Naproxen—ALB—Metabolism—RRM2—urinary bladder cancer	9.04e-06	0.00016	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MYC—urinary bladder cancer	9.03e-06	0.00016	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ERBB2—urinary bladder cancer	8.92e-06	0.000158	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.89e-06	0.000158	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—urinary bladder cancer	8.83e-06	0.000157	CbGpPWpGaD
Naproxen—ALB—Hemostasis—CREBBP—urinary bladder cancer	8.78e-06	0.000156	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTP1—urinary bladder cancer	8.76e-06	0.000155	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	8.73e-06	0.000155	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PPARG—urinary bladder cancer	8.71e-06	0.000155	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—EP300—urinary bladder cancer	8.68e-06	0.000154	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IGF1—urinary bladder cancer	8.67e-06	0.000154	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NAT2—urinary bladder cancer	8.57e-06	0.000152	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.48e-06	0.00015	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—urinary bladder cancer	8.46e-06	0.00015	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	8.42e-06	0.000149	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ENO2—urinary bladder cancer	8.42e-06	0.000149	CbGpPWpGaD
Naproxen—ALB—Metabolism—HPGDS—urinary bladder cancer	8.37e-06	0.000148	CbGpPWpGaD
Naproxen—ALB—Metabolism—ENO2—urinary bladder cancer	8.37e-06	0.000148	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.37e-06	0.000148	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	8.37e-06	0.000148	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NQO1—urinary bladder cancer	8.34e-06	0.000148	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KRAS—urinary bladder cancer	8.34e-06	0.000148	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.32e-06	0.000148	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	8.17e-06	0.000145	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—TYMS—urinary bladder cancer	8.15e-06	0.000144	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.12e-06	0.000144	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTT1—urinary bladder cancer	8.12e-06	0.000144	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMP—urinary bladder cancer	8.1e-06	0.000144	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2—urinary bladder cancer	8.08e-06	0.000143	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTM1—urinary bladder cancer	8.05e-06	0.000143	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—NCOR1—urinary bladder cancer	8.05e-06	0.000143	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.04e-06	0.000143	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8e-06	0.000142	CbGpPWpGaD
Naproxen—ALB—Hemostasis—RHOA—urinary bladder cancer	7.95e-06	0.000141	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—urinary bladder cancer	7.88e-06	0.00014	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.78e-06	0.000138	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GPX1—urinary bladder cancer	7.71e-06	0.000137	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—urinary bladder cancer	7.65e-06	0.000136	CbGpPWpGaD
Naproxen—PTGS2—Disease—NCOR1—urinary bladder cancer	7.63e-06	0.000135	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN1A—urinary bladder cancer	7.62e-06	0.000135	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTEN—urinary bladder cancer	7.61e-06	0.000135	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.6e-06	0.000135	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	7.59e-06	0.000135	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ERCC2—urinary bladder cancer	7.57e-06	0.000134	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—RRM2—urinary bladder cancer	7.4e-06	0.000131	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NAT2—urinary bladder cancer	7.33e-06	0.00013	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	7.29e-06	0.000129	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EP300—urinary bladder cancer	7.25e-06	0.000129	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERCC2—urinary bladder cancer	7.18e-06	0.000127	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—MTHFR—urinary bladder cancer	7.12e-06	0.000126	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—urinary bladder cancer	7.09e-06	0.000126	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPARG—urinary bladder cancer	7.08e-06	0.000126	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.06e-06	0.000125	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SRC—urinary bladder cancer	7.05e-06	0.000125	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTP1—urinary bladder cancer	6.96e-06	0.000123	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	6.85e-06	0.000122	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ENO2—urinary bladder cancer	6.85e-06	0.000122	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	6.85e-06	0.000122	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.81e-06	0.000121	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	6.8e-06	0.000121	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NQO1—urinary bladder cancer	6.79e-06	0.00012	CbGpPWpGaD
Naproxen—ALB—Metabolism—NQO1—urinary bladder cancer	6.75e-06	0.00012	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTHFR—urinary bladder cancer	6.75e-06	0.00012	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.73e-06	0.000119	CbGpPWpGaD
Naproxen—PTGS2—Disease—TERT—urinary bladder cancer	6.73e-06	0.000119	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—urinary bladder cancer	6.67e-06	0.000118	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	6.65e-06	0.000118	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.59e-06	0.000117	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.55e-06	0.000116	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.55e-06	0.000116	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—TYMS—urinary bladder cancer	6.47e-06	0.000115	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTM1—urinary bladder cancer	6.39e-06	0.000113	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NCOR1—urinary bladder cancer	6.39e-06	0.000113	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—RRM2—urinary bladder cancer	6.32e-06	0.000112	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—urinary bladder cancer	6.32e-06	0.000112	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—urinary bladder cancer	6.18e-06	0.00011	CbGpPWpGaD
Naproxen—PTGS2—Disease—FGFR3—urinary bladder cancer	6.17e-06	0.00011	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GPX1—urinary bladder cancer	6.12e-06	0.000109	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ERCC2—urinary bladder cancer	6.01e-06	0.000107	CbGpPWpGaD
Naproxen—ALB—Hemostasis—EP300—urinary bladder cancer	5.98e-06	0.000106	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—urinary bladder cancer	5.98e-06	0.000106	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	5.97e-06	0.000106	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	5.86e-06	0.000104	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ENO2—urinary bladder cancer	5.86e-06	0.000104	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—urinary bladder cancer	5.84e-06	0.000104	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.82e-06	0.000103	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SRC—urinary bladder cancer	5.82e-06	0.000103	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPARG—urinary bladder cancer	5.77e-06	0.000102	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.74e-06	0.000102	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.71e-06	0.000101	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—EP300—urinary bladder cancer	5.7e-06	0.000101	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	5.68e-06	0.000101	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	5.66e-06	0.0001	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—MTHFR—urinary bladder cancer	5.65e-06	0.0001	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTP1—urinary bladder cancer	5.63e-06	9.98e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.59e-06	9.92e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	5.57e-06	9.88e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CREBBP—urinary bladder cancer	5.55e-06	9.83e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NQO1—urinary bladder cancer	5.52e-06	9.8e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.48e-06	9.71e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.45e-06	9.66e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.36e-06	9.51e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMS—urinary bladder cancer	5.26e-06	9.33e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CREBBP—urinary bladder cancer	5.26e-06	9.32e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMS—urinary bladder cancer	5.23e-06	9.28e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	5.21e-06	9.23e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	5.2e-06	9.23e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	5.2e-06	9.23e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—urinary bladder cancer	5.19e-06	9.21e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTM1—urinary bladder cancer	5.17e-06	9.17e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NCOR1—urinary bladder cancer	5.17e-06	9.17e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GPX1—urinary bladder cancer	4.98e-06	8.84e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—urinary bladder cancer	4.97e-06	8.8e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—EP300—urinary bladder cancer	4.96e-06	8.8e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GPX1—urinary bladder cancer	4.95e-06	8.78e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	4.89e-06	8.67e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ERCC2—urinary bladder cancer	4.86e-06	8.63e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—urinary bladder cancer	4.86e-06	8.61e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—urinary bladder cancer	4.82e-06	8.54e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—RHOA—urinary bladder cancer	4.76e-06	8.43e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NQO1—urinary bladder cancer	4.72e-06	8.37e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.67e-06	8.29e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—EP300—urinary bladder cancer	4.63e-06	8.22e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	4.61e-06	8.17e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	4.6e-06	8.15e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPARG—urinary bladder cancer	4.58e-06	8.13e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.58e-06	8.12e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—MTHFR—urinary bladder cancer	4.57e-06	8.11e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—urinary bladder cancer	4.54e-06	8.05e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.46e-06	7.91e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CREBBP—urinary bladder cancer	4.4e-06	7.81e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—urinary bladder cancer	4.4e-06	7.81e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.28e-06	7.6e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—urinary bladder cancer	4.28e-06	7.59e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.23e-06	7.51e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.23e-06	7.51e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—urinary bladder cancer	4.09e-06	7.26e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GPX1—urinary bladder cancer	4.05e-06	7.19e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.99e-06	7.08e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.98e-06	7.06e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—urinary bladder cancer	3.96e-06	7.02e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	3.94e-06	6.98e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.81e-06	6.76e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—EP300—urinary bladder cancer	3.78e-06	6.7e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1A—urinary bladder cancer	3.76e-06	6.67e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—urinary bladder cancer	3.75e-06	6.66e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.74e-06	6.64e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPARG—urinary bladder cancer	3.73e-06	6.61e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPARG—urinary bladder cancer	3.71e-06	6.57e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.66e-06	6.49e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.62e-06	6.42e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.62e-06	6.42e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	3.58e-06	6.35e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EP300—urinary bladder cancer	3.58e-06	6.35e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CREBBP—urinary bladder cancer	3.56e-06	6.32e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—SRC—urinary bladder cancer	3.48e-06	6.17e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.47e-06	6.14e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.4e-06	6.03e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	3.2e-06	5.67e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—urinary bladder cancer	3.14e-06	5.57e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—urinary bladder cancer	3.12e-06	5.53e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—urinary bladder cancer	3.05e-06	5.41e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.03e-06	5.38e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—EP300—urinary bladder cancer	3e-06	5.32e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	2.93e-06	5.2e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—urinary bladder cancer	2.92e-06	5.17e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.92e-06	5.17e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—urinary bladder cancer	2.88e-06	5.11e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.59e-06	4.6e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—urinary bladder cancer	2.56e-06	4.54e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—urinary bladder cancer	2.54e-06	4.51e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.49e-06	4.42e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—urinary bladder cancer	2.45e-06	4.34e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—EP300—urinary bladder cancer	2.44e-06	4.33e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—EP300—urinary bladder cancer	2.43e-06	4.3e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.39e-06	4.23e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.08e-06	3.69e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	2.04e-06	3.62e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.99e-06	3.52e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.78e-06	3.15e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.7e-06	3.01e-05	CbGpPWpGaD
